Dalbavancin: A novel antimicrobial

A. Y. Chen, M. J. Zervos, J. A. Vazquez

Research output: Contribution to journalReview articlepeer-review

94 Scopus citations


The increasing incidence of serious infections because of Gram-positive pathogens and the rising cost in parenteral administration of antimicrobials has inspired the development of a novel antibiotic. Dalbavancin is the first once a week antibiotic with activity against a broad range of Gram-positive pathogens. A large multicentre, pivotal, Phase III clinical trial, which included 854 patients with complicated skin and skin structure infections, compared 1-2 doses of dalbavancin vs. linezolid. The results demonstrated non-inferiority and a comparable safety profile. With its unique pharmacokinetic profile, ease of use and excellent safety profile, dalbavancin should provide a valuable addition to the armamentarium used to treat infections because of Gram-positive cocci.

Original languageEnglish (US)
Pages (from-to)853-863
Number of pages11
JournalInternational Journal of Clinical Practice
Issue number5
StatePublished - May 2007
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Dalbavancin: A novel antimicrobial'. Together they form a unique fingerprint.

Cite this